3,5-Dioxo-1-piperazinecarboxylic acid 1,1-dimethylethyl ester

Catalog No. :
ACEGQD074
CAS No. :
501127-89-5
Molecular Formula :
C9H14N2O4
Molecular Weight :
214.22

IUPAC Name:tert-butyl 3,5-dioxopiperazine-1-carboxylate

3,5-Dioxo-1-piperazinecarboxylic acid 1,1-dimethylethyl ester structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$69.00Login to see priceIn stockIn stock
5g97%$337.00Login to see priceIn stockIn stock
25g97%$1584.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3,5-Dioxo-1-piperazinecarboxylic acid 1,1-dimethylethyl ester
IUPAC Nametert-butyl 3,5-dioxopiperazine-1-carboxylate
MDL No.MFCD16990495
Molecular FormulaC9H14N2O4
Molecular Weight214.22
SMILESO=C(N1CC(NC(C1)=O)=O)OC(C)(C)C
InChI KeyRUVRAIGXERUAHV-UHFFFAOYSA-N
Synonymtert-butyl 3,5-dioxopiperazine-1-carboxylate;3,5-Dioxo-1-piperazinecarboxylic acid 1,1-dimethylethyl ester;1-Piperazinecarboxylic acid, 3,5-dioxo-, 1,1-dimethylethyl ester;4-Boc-piperazine-2,6-dione;1-Boc-3,5-dioxopiperazine;3,5-Dioxo-1-piperazinecarboxylic acid 1,1-dimethylethyl este
CAS No.501127-89-5
PubChem CID59834673

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACEGQD074 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACLSVO463 route compound structure diagram
    ACLSVO4634774-22-5 In Stock
  4. Then
  5. ACEGQD074 route product structure diagram
    ACEGQD074501127-89-5 In Stock
Inquiry

2. ACEGQD074 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEGQD074 route product structure diagram
    ACEGQD074501127-89-5 In Stock
Inquiry

Comments (0)